CannTrust Holdings Inc (TRST) Director Buys C$171,684.00 in Stock

CannTrust Holdings Inc (CNSX:TRST) Director Aubrey Dan acquired 17,100 shares of the stock in a transaction dated Friday, January 12th. The stock was purchased at an average cost of C$10.04 per share, with a total value of C$171,684.00.

Aubrey Dan also recently made the following trade(s):

  • On Monday, January 15th, Aubrey Dan acquired 173 shares of CannTrust stock. The stock was purchased at an average cost of C$10.34 per share, with a total value of C$1,788.82.

CannTrust Holdings Inc (CNSX:TRST) traded up C$0.14 during trading on Friday, hitting C$10.97. The stock had a trading volume of 273,209 shares, compared to its average volume of 47,077. CannTrust Holdings Inc has a one year low of C$1.69 and a one year high of C$11.00. The firm has a market capitalization of $997.24 and a P/E ratio of -548.50.

Separately, Canaccord Genuity upped their price objective on CannTrust from $7.25 to $9.50 in a research note on Monday, December 4th.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/19/canntrust-holdings-inc-trst-director-buys-c171684-00-in-stock.html.

CannTrust Company Profile

CannTrust Holdings Inc is a Canada-based company, which produces pharmaceutical-grade medical cannabis for patients. The Company is a federally regulated licensed producer of medical cannabis products. The Company operates a hydroponic facility and an onsite laboratory for testing and research on the medical use of cannabis.

Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply